CNS Demyelinating Disease Evaluation, Serum
Use
This test is useful for diagnosing inflammatory demyelinating diseases (IDDs) that have a similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), such as optic neuritis and transverse myelitis. It discriminates NMOSD, acute disseminated encephalomyelitis (ADEM), and other conditions from multiple sclerosis early in the disease course. It aids in diagnosing ADEM, autoimmune myelin oligodendrocyte glycoprotein-opathy, and neuromyelitis optica, predicting a relapsing disease course, and guiding appropriate treatment strategies to prevent symptom exacerbation, especially in cases with a distinct diagnosis from multiple sclerosis.
Special Instructions
Not provided.
Limitations
Aquaporin-4-IgG and myelin oligodendrocyte glycoprotein-IgG antibodies might drop below detectable levels during acute attack therapies or attack prevention treatments. The test may not eliminate all possibilities of false results if antibodies fall below detection thresholds due to treatment effects.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 102085-8 - CNS Demyelinating ds Panel SerPl FC
- 43638-6 - AQP4 H2O channel IgG SerPl Ql
- 90248-6 - MOG IgG1 SerPl Ql FC
- 69048-7 - Immunologist review
Result Turnaround Time
7-10 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
2 mL
Container
Red top or Serum gel; submission in plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Patient Preparation
For optimal antibody detection, specimen collection is recommended before initiation of immunosuppressant medication.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |